In a report released today, Swayampakula Ramakanth from H.C. Wainwright maintained a Buy rating on EDAP TMS (NASDAQ: EDAP), with a price target of $6.50. The company’s shares opened today at $3.03.
Ramakanth commented:
“We are maintaining our Buy rating of EDAP TMS and our 12-month price target of $6.50 per diluted ADS. We derived our price target based on the average of two valuation methods: (1) price-earnings multiple using 25x 2026 EPS estimate discounted at 12%; and (2) discounted cash flow analysis using a 2% terminal growth rate and discounting 2026 free cash flow estimate at a 12% discount rate. (1) commercial; (2) regulatory; (3) currency; (4) reimbursement; and (5) intellectual property.”
According to TipRanks.com, Ramakanth is a 4-star analyst with an average return of 7.2% and a 38.3% success rate. Ramakanth covers the Healthcare sector, focusing on stocks such as Diffusion Pharmaceuticals Inc, IntelGenx Technologies, and Leap Therapeutics Inc.
Currently, the analyst consensus on EDAP TMS is a Moderate Buy with an average price target of $6.50.
See today’s analyst top recommended stocks >>
The company has a one-year high of $4.25 and a one-year low of $2.07. Currently, EDAP TMS has an average volume of 640.2K.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
EDAP TMS SA develops, produces and markets minimally invasive medical devices for urological diseases. HIFU treatment is shown to be a minimally invasive and effective treatment option with a low occurrence of side effects.
